These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21131918)

  • 21. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
    J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma: A Reclassification Study by the Spanish Group for Ovarian Cancer Research (GEICO).
    Leskela S; Romero I; Cristobal E; Pérez-Mies B; Rosa-Rosa JM; Gutierrez-Pecharroman A; Santón A; Gonzalez BO; López-Reig R; Hardisson D; Vera-Sempere F; Illueca C; Vieites B; López-Guerrero JA; Palacios J; Poveda A
    Am J Surg Pathol; 2020 Feb; 44(2):149-161. PubMed ID: 31498173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype.
    Köbel M; Xu H; Bourne PA; Spaulding BO; Shih IeM; Mao TL; Soslow RA; Ewanowich CA; Kalloger SE; Mehl E; Lee CH; Huntsman D; Gilks CB
    Mod Pathol; 2009 Mar; 22(3):469-75. PubMed ID: 19136932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reproducibility of histological cell type in high-grade endometrial carcinoma.
    Han G; Sidhu D; Duggan MA; Arseneau J; Cesari M; Clement PB; Ewanowich CA; Kalloger SE; Köbel M
    Mod Pathol; 2013 Dec; 26(12):1594-604. PubMed ID: 23807777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma.
    Phillips V; Kelly P; McCluggage WG
    Int J Gynecol Pathol; 2009 Mar; 28(2):179-86. PubMed ID: 19188815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
    Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
    Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differentiation of epithelial ovarian cancer subtypes by use of imaging and clinical data: a detailed analysis.
    Tanaka YO; Okada S; Satoh T; Matsumoto K; Oki A; Saida T; Yoshikawa H; Minami M
    Cancer Imaging; 2016 Feb; 16():3. PubMed ID: 26873307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites.
    Köbel M; Turbin D; Kalloger SE; Gao D; Huntsman DG; Gilks CB
    Int J Gynecol Pathol; 2011 Jul; 30(4):366-71. PubMed ID: 21623201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary.
    El-Balat A; Schmeil I; Karn T; Becker S; Sänger N; Holtrich U; Arsenic R
    Pathol Oncol Res; 2018 Apr; 24(2):277-282. PubMed ID: 28470574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic value of dual detection of hepatocyte nuclear factor 1 beta (HNF-1β) and napsin A for diagnosing ovarian clear cell carcinoma.
    Li Q; Zeng X; Cheng X; Zhang J; Ji J; Wang J; Xiong K; Qi Q; Huang W
    Int J Clin Exp Pathol; 2015; 8(7):8305-10. PubMed ID: 26339401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas.
    Nonaka D; Chiriboga L; Soslow RA
    Am J Surg Pathol; 2008 Oct; 32(10):1566-71. PubMed ID: 18724243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy.
    Wiedemeyer K; Köbel M; Koelkebeck H; Xiao Z; Vashisht K
    Hum Pathol; 2020 Apr; 98():56-63. PubMed ID: 32017945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving histotyping precision: The impact of immunohistochemical algorithms on epithelial ovarian cancer classification.
    Zelisse HS; Dijk F; van Gent MDJM; Hooijer GKJ; Mom CH; van de Vijver MJ; Snijders MLH
    Hum Pathol; 2024 Sep; 151():105631. PubMed ID: 39084566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis.
    Gagné A; Têtu B; Orain M; Turcotte S; Plante M; Grégoire J; Renaud MC; Bairati I; Trudel D
    Diagn Pathol; 2018 Aug; 13(1):57. PubMed ID: 30131069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
    Cheasley D; Nigam A; Zethoven M; Hunter S; Etemadmoghadam D; Semple T; Allan P; Carey MS; Fernandez ML; Dawson A; Köbel M; Huntsman DG; Le Page C; Mes-Masson AM; Provencher D; Hacker N; Gao Y; Bowtell D; deFazio A; Gorringe KL; Campbell IG
    J Pathol; 2021 Jan; 253(1):41-54. PubMed ID: 32901952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis of Ovarian Carcinoma Histotype Based on Limited Sampling: A Prospective Study Comparing Cytology, Frozen Section, and Core Biopsies to Full Pathologic Examination.
    Hoang LN; Zachara S; Soma A; Köbel M; Lee CH; McAlpine JN; Huntsman D; Thomson T; van Niekerk D; Singh N; Gilks CB
    Int J Gynecol Pathol; 2015 Nov; 34(6):517-27. PubMed ID: 26107565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.
    Sundov D; Caric A; Mrklic I; Gugic D; Capkun V; Hofman ID; Mise BP; Tomic S
    Diagn Pathol; 2013 Feb; 8():21. PubMed ID: 23388101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma.
    Rosen DG; Cai KQ; Luthra R; Liu J
    Mod Pathol; 2006 Nov; 19(11):1414-20. PubMed ID: 16941012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
    Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
    Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.